Kodiak Sciences Inc stock drops 2.6% just before major AMD trial win

What happened

Kodiak Sciences stock closed at $32 on September 25, down 2.6%, with a corrective daily chart. Positive wet AMD trial data for Zenkuda was disclosed on September 28, and Cantor Fitzgerald reiterated its Overweight rating.

Confirmed

Global impact / market context

Positive trial results for a drug treating wet AMD, an eye disease that damages central vision, can raise hopes for future sales. Cantor Fitzgerald's Overweight rating suggests analysts still see value despite the recent share price decline and corrective chart.

Analyst inference

The stock fell before the trial news and analyst rating, so those positive events were not reflected in the earlier close. If investors reprice the shares to reflect the clinical catalyst, the stock could move toward the analyst's more optimistic view.

Analyst inference

What to watch

1. The article states the daily chart remains corrective before the trial data and rating, so the prior price trend may not yet reflect those newer positive events. Confirmed
2. Investors could watch whether the stock later closes above its confirmed September 25 close, as a sign the trial news is being priced in. Proposed
3. Watch for more detail on the wet AMD trial results or any change to the Cantor Fitzgerald Overweight rating, since these could alter expectations for Zenkuda's future revenue. Analyst inference

Evidence

• en.cryptonomist.ch